Sarepta Therapeutics Stock (NASDAQ: SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) Stock, Quote.Headers.trade-ideas

Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Biotech

News

Health Care

Movers

General

SRPT

Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful functional improvements.

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy

Monster Energy logo

Large Cap

ABNB

DELL

MNST

SBAC

SMCI

TECH

These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers.

Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?

McKesson

Pre-Market Outlook

Markets

Trading Ideas

BMBL

BROS

CDLX

FROG

FSLY

McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics Inc

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

AMGN

EXAS

ILMN

MRNA

RPRX

10 Health Care Stocks With Whale Alerts In Today's Session

Ratings for Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) were provided by 26 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $188.31, a high estimate of $235.00, and a low estimate of $128.00. This current average reflects an increase of 7.65% from the previous average price target of $174.92. 
<img src="https://www.benzinga.com/files/images/story/2024/1725642101_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Sarepta Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$179.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$203.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$182.00</td>
<td>-</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$235.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$176.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$185.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Mani Foroohar</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$157.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$128.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$182.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$226.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$213.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sarepta Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>About Sarepta Therapeutics</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
<h3>Key Indicators: Sarepta Therapeutics's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Sarepta Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 38.93%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sarepta Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of 1.78%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Sarepta Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.63%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Sarepta Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.19% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Sarepta Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 1.27, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Unveiling 26 Analyst Insights On Sarepta Therapeutics

RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and maintains $181 price target.

Price Target

Reiteration

RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $181 Price Target

On Tuesday, Dyne Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40682278/dyne-therapeutics-announces-new-clinical-data-from-phase-12-deliver-trial-of-dyne-251-in-duchenne-" rel="noreferrer noopener">amenable to exon 51 skipping</a>.
This assessment of the DELIVER trial evaluating DYNE-251 includes 6-month biomarker and functional data from 8 male patients enrolled in the 20 mg/kg (approximate PMO dose) cohort who were randomized to receive DYNE-251 or placebo once every four weeks and 12-month functional data from 6 participants in the 10 mg/kg cohort.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38925997/why-is-dyne-therapeutics-stock-soaring-on-monday" rel="noreferrer noopener">Why Is Dyne Therapeutics Stock Soaring On Monday?</a>
At a 20-mg/kg dose level, given every four weeks, DYNE-251 resulted in a mean absolute dystrophin expression of 3.71% of normal, without adjusting for muscle content.
The company noted that the expression level is more than ten times higher than in a reference clinical trial assessing the weekly standard of care treatment Sarepta Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) EXONDYS 51 (eteplirsen), where dystrophin expression was at 0.3% normal.
After controlling for patients&#8217; muscle content, the company said that the mean absolute dystrophin expression jumped to 8.72%, which exceeds levels typically recorded in studies evaluating other investigational oligomers for DMD.
These results are in line with&nbsp;six-month data&nbsp;Dyne released in May for patients treated with the 10-mg/kg <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38925997/why-is-dyne-therapeutics-stock-soaring-on-monday" rel="noreferrer noopener">dose of DYNE-251</a>.
Patients treated with 10 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin level of 3.22% of normal and a 2.97% change (unadjusted for muscle content) from baseline at&nbsp;six&nbsp;months.&nbsp;
When adjusting for muscle content, the&nbsp;DYNE-251 treated&nbsp;group reached 7.64% mean absolute dystrophin.
Dyne Therapeutics says&nbsp;meaningful improvements in multiple functional endpoints were observed in the 20 mg/kg and 10 mg/kg DYNE-251 Q4W groups. The 10 mg/kg cohort showed continued improvement in all reported measures from 6 to 12 months.
DYNE-251 demonstrated a favorable safety profile, and most treatment-emergent adverse events were mild or moderate.
Dyne says it is initiating registrational cohorts in the DELIVER trial and plans to provide an update on the path to registration by the end of 2024.
Price Action: DYN stock is down 31.90% at $31.39 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40688264/bacterial-infections-vaccine-developer-vaxcytes-pneumococcal-shot-shows-promise-in-mid-stage-tria" target="_blank" rel="noreferrer noopener">Bacterial Infections Vaccine Developer Vaxcyte&#8217;s Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher</a>.</li>
</ul>

Sarepta Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NYSE">SRPT</a>) short percent of float has fallen 9.25% since its last report. The company recently reported that it has 6.72 million shares sold short, which is 7.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sarepta Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723824915_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sarepta Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Sarepta Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sarepta Therapeutics's peer group average for short interest as a percentage of float is 6.18%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) has been analyzed by 28 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $185.0, a high estimate of $235.00, and a low estimate of $128.00. This current average has increased by 6.54% from the previous average price target of $173.65. 
<img src="https://www.benzinga.com/files/images/story/2024/1723737633_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Sarepta Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$179.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$203.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$182.00</td>
<td>-</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$235.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$176.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$185.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Mani Foroohar</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$157.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$128.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$182.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$226.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$213.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$157.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$142.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$166.00</td>
<td>$166.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sarepta Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Sarepta Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sarepta Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>Discovering Sarepta Therapeutics: A Closer Look</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
<h3>Understanding the Numbers: Sarepta Therapeutics's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Sarepta Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 38.93%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Sarepta Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.78% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sarepta Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.63%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Sarepta Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.19%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.27.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics

Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) has outperformed the market over the past 10 years by 8.48% on an annualized basis producing an average annual return of 18.89%. Currently, Sarepta Therapeutics has a market capitalization of $12.10 billion. 
Buying $100 In SRPT: If an investor had bought $100 of SRPT stock 10 years ago, it would be worth $564.27 today based on a price of $126.85 for SRPT at the time of writing.
<h3>Sarepta Therapeutics's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723473017_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) shares decreased 12.06% after reporting worse-than-expected <a href="https://www.benzinga.com//node/40232820" target="_blank" rel="noreferrer noopener">first-quarter FY25 sales results</a>. Analysts revised <a href="https://www.benzinga.com/quote/mck/analyst-ratings" target="_blank" rel="noreferrer noopener">the company&#8217;s price targets</a>.</li>
<li>BIO-TECHNE Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) stock 11.71% value last week on worse-than-expected Q4 revenue results.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) stock declined 10.62% following weak <a href="https://www.benzinga.com//node/40234107" target="_blank" rel="noreferrer noopener">second-quarter financial results</a>. Several analysts updated their ratings <a href="https://www.benzinga.com//node/40264035" target="_blank" rel="noreferrer noopener">and price targets on the stock</a>.</li>
<li>Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares dipped 10.41% on Q2 results and cut its FY24 <a href="https://www.benzinga.com//node/40222523" target="_blank" rel="noreferrer noopener">adjusted outlook</a>. Analysts lowered the <a href="https://www.benzinga.com/quote/crl/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock fell 9.33% on worse-than-expected Q2 sales results. The company issued FY25 net product revenue guidance below estimates, and several analysts <a href="https://www.benzinga.com/quote/srpt/analyst-ratings" target="_blank" rel="noreferrer noopener">cut their price forecasts</a> for the stock.</li>
<li>Monster Beverage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) stock plummeted 8.95% after the company reported <a href="https://www.benzinga.com//node/40233200" target="_blank" rel="noreferrer noopener">Q2 financial results</a>. Many analysts <a href="https://www.benzinga.com/quote/mnst/analyst-ratings" target="_blank" rel="noreferrer noopener">cut the price target</a>.</li>
<li>TopBuild Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) stock dived 8.93% following worse-<a href="https://www.benzinga.com//node/40182863" target="_blank" rel="noreferrer noopener">than-expected quarterly results</a>. Several analysts lowered the price <a href="https://www.benzinga.com/quote/bld/analyst-ratings" target="_blank" rel="noreferrer noopener">target on the company</a>.</li>
<li>Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) stock dived 7.01% after the company reported worse-than-expected quarterly EPS results and issued <a href="https://www.benzinga.com//node/40203008" target="_blank" rel="noreferrer noopener">third-quarter revenue guidance below estimates</a>. Many analysts slashed the <a href="https://www.benzinga.com//node/40227192" target="_blank" rel="noreferrer noopener">price target and forecast on the stock</a>.</li>
<li>Advanced Drainage Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) stock fell 6.94% <a href="https://www.benzinga.com//node/40246477" target="_blank" rel="noreferrer noopener">following a quarterly earnings miss</a>.</li>
<li>SBA Communications Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) stock fell 6.85% in the last week.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40303526/shopify-palantir-and-uber-are-among-top-10-large-cap-gainers-last-week-aug-4-aug-10-are-the-others-i" target="_blank" rel="noreferrer noopener">Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

WIIM

Sarepta Therapeutics shares are trading lower after the company on Wednesday reported worse-than-expected Q2 sales results and issued FY25 net product revenue guidance below estimates.

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and lowers the price target from $182 to $181.

RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $181

Whales with a lot of money to spend have taken a noticeably bullish stance on Sarepta Therapeutics.
Looking at options history for Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 38% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $368,057 and 4, calls, for a total amount of $348,950.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $165.0 for Sarepta Therapeutics, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Sarepta Therapeutics options trades today is 293.44 with a total volume of 904.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Sarepta Therapeutics's big money trades within a strike price range of $55.0 to $165.0 over the last 30 days.
<h3>Sarepta Therapeutics Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723145475_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$35.0</td>
<td>$33.4</td>
<td>$35.0</td>
<td>$100.00</td>
<td>$175.0K</td>
<td style="text-align: right;">120</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$82.6</td>
<td>$79.3</td>
<td>$81.25</td>
<td>$55.00</td>
<td>$81.2K</td>
<td style="text-align: right;">82</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.6</td>
<td>$9.5</td>
<td>$9.5</td>
<td>$125.00</td>
<td>$67.4K</td>
<td style="text-align: right;">91</td>
<td style="text-align: right;">76</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$33.1</td>
<td>$33.0</td>
<td>$33.0</td>
<td>$100.00</td>
<td>$49.5K</td>
<td style="text-align: right;">120</td>
<td style="text-align: right;">65</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/09/24</td>
<td>$4.4</td>
<td>$1.95</td>
<td>$2.15</td>
<td>$134.00</td>
<td>$44.9K</td>
<td style="text-align: right;">425</td>
<td style="text-align: right;">54</td>
</tr>
</tbody>
</table>

<h3>About Sarepta Therapeutics</h3>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Following our analysis of the options activities associated with Sarepta Therapeutics, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Sarepta Therapeutics</h3>
<ul>
<li>With a volume of 2,656,675, the price of SRPT is down -3.62% at $134.99. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>Expert Opinions on Sarepta Therapeutics</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $179.4.
<ul>
<li>An analyst from Barclays has decided to maintain their Overweight rating on Sarepta Therapeutics, which currently sits at a price target of $203. </li>
<li>Showing optimism, an analyst from RBC Capital upgrades its rating to Outperform with a revised price target of $182. </li>
<li>An analyst from Piper Sandler has decided to maintain their Overweight rating on Sarepta Therapeutics, which currently sits at a price target of $200. </li>
<li>An analyst from Cantor Fitzgerald persists with their Neutral rating on Sarepta Therapeutics, maintaining a target price of $152. </li>
<li>An analyst from Citigroup persists with their Neutral rating on Sarepta Therapeutics, maintaining a target price of $160. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Sarepta Therapeutics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Smart Money Is Betting Big In SRPT Options

Citigroup analyst David Hoang maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and lowers the price target from $176 to $160.

Citigroup Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $160

Cantor Fitzgerald analyst Kristen Kluska maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and lowers the price target from $167 to $152.

Cantor Fitzgerald Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $152

Evercore ISI Group analyst Gavin Clark-Gartner upgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from In-Line to Outperform and lowers the price target from $185 to $179.

Upgrades

Evercore ISI Group Upgrades Sarepta Therapeutics to Outperform, Lowers Price Target to $179

Barclays analyst Gena Wang maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $226 to $203.

Barclays Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $203

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.2% on Thursday.
Shares of McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/MCK/earnings">first-quarter sales results.</a>
McKesson reported quarterly earnings of $7.88 per share which beat the analyst consensus estimate of $7.21 per share. The company reported quarterly sales of $79.30 billion which missed the analyst consensus estimate of $82.53 billion.
McKesson shares dipped 7.1% to $574.00 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Cardlytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) shares dipped 49.6% to $3.48 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) shares declined 39.8% to $4.85 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>JFrog Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) fell 27.4% to $24.73 pre-market trading after the company reported worse-than-expected second-quarter revenue results. Additionally, the company issued FY24 guidance below estimates.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares fell 20.7% to $29.89 in pre-market trading after the company reported second-quarter results.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) fell 20.5% to $5.42 in pre-market trading after the company issued FY24 guidance below estimates.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) dipped 12.2% to $6.77 in pre-market trading following second-quarter financial results, which included a decline in advertising revenue.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares fell 8.6% to $127.93 after the company reported worse-than-expected quarterly sales results.</li>
<li>Monster Beverage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) dipped 8.3% to $46.35 after the company reported worse-than-expected second-quarter financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40218858/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Sarepta Therapeutics shares are trading lower after the company reported worse-than-expected Q2 sales results and issued FY25 net product revenue guidance below estimates. Also, Piper Sandler maintained an Overweight rating on the stock and lowered its price target from $205 to $200.

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $205 to $200.

Piper Sandler Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $200

Guidance

Sarepta Therapeutics Sees FY25 Net Product Revenue $2.9B-$3.1B Vs $3.24B Estimate

RBC Capital analyst Brian Abrahams maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $181.00...

RBC Capital Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

AVK: Trying To Take Advantage Of Market Developments, But Hard To Justify A Premium

These are the stocks with the largest changes in short interest in July - GS

Dyne stock tumbles 31% amid drug updates, management changes

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Russell companies with the lowest tax rates expected to generate $1B in 2025 – GS

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and Da...

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Danaher (DHR)

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target ...

Sarepta Therapeutics (SRPT) Gets a Buy from TD Cowen

The latest update is out from Sarepta Therapeutics ( ($SRPT) ). Sarepta Therapeutics, Inc. has welcomed Deirdre Connelly to its board of directors,...

Sarepta Therapeutics Expands Board, Welcomes New Director

Sarepta Therapeutics Muscles Up In DMD Race

ABBV

ACGL

ALAB

ALLY

AMAT

ARES

AVGO

AVTR

BACRP

BIRK

BRBR

BSQKZ

CAPR

CART

CFLT

CHRD

CPRX

CRWD

CUKPF

CVNA

DXCM

EWTX

FSLR

ICVT

INTC

JAZZ

KEYS

KLAC

LRCX

LUMN

MASI

MCHP

MDGL

MRVL

MSCLF

MTDR

NCLH

NTRA

PACS

PEPG

QCOM

REGN

RGNX

RHHBY

RIVN

RYAN

SAIA

SIRI

SLDB

SMMT

SNPS

SPOT

SWKS

TRDA

TRGP

UBER

VERX

VRTX

WFRD

XLRE

Press Releases

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Management

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results

Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Sarepta Therapeutics

Sarepta Therapeutics (SRPT) Forecast

Sarepta Therapeutics (NASDAQ:SRPT) Stock, Quote.Headers.trade-ideas